NCT02393248 · OUTCOME

Parts 1 and 2: AUClast After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) · Source last updated 2023-01-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: hr*ng/mL
Interval / dispersion: Standard Deviation
Time frame: Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1

What was measured

AUClast was defined as the area under the plasma or serum concentration-time curve from the time of dosing to the last measurable concentration.

Analysis population: PK/PD Population. Only participants with available data were analyzed.

Groups in this outcome

Part 1: Intermittent Pemigatinib 1 mg QD

Participants self-administered oral pemigatinib 1 milligram (mg) once daily (QD) on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

Part 1: Intermittent Pemigatinib 2 mg QD

Participants self-administered oral pemigatinib 2 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

Part 1: Intermittent Pemigatinib 4 mg QD

Participants self-administered oral pemigatinib 4 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

Part 1: Intermittent Pemigatinib 6 mg QD

Participants self-administered oral pemigatinib 6 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.

Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD

Participants self-administered intermittent or continuous oral pemigatinib 9 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.

Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD

Participants self-administered intermittent or continuous oral pemigatinib 13.5 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.

Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD

Participants self-administered intermittent or continuous oral pemigatinib 20 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 20 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Part 1: Intermittent Pemigatinib 1 mg QD	1
Part 1: Intermittent Pemigatinib 2 mg QD	1
Part 1: Intermittent Pemigatinib 4 mg QD	1
Part 1: Intermittent Pemigatinib 6 mg QD	4
Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD	21
Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD	69
Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD	69

Reported measurements

Source class 1

Values in hr*ng/mL · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Part 1: Intermittent Pemigatinib 1 mg QD	190	NA	Not reported	Not reported	A standard deviation was not calculated for a single participant.
Part 1: Intermittent Pemigatinib 2 mg QD	68.8	NA	Not reported	Not reported	A standard deviation was not calculated for a single participant.
Part 1: Intermittent Pemigatinib 4 mg QD	1010	NA	Not reported	Not reported	A standard deviation was not calculated for a single participant.
Part 1: Intermittent Pemigatinib 6 mg QD	641	116	Not reported	Not reported	Not reported
Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD	1140	498	Not reported	Not reported	Not reported
Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD	1820	1210	Not reported	Not reported	Not reported
Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD	2510	935	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
comment
A standard deviation was not calculated for a single participant.
group Id
OG000
spread
NA
value
190
comment
A standard deviation was not calculated for a single participant.
group Id
OG001
spread
NA
value
68.8
comment
A standard deviation was not calculated for a single participant.
group Id
OG002
spread
NA
value
1010
group Id
OG003
spread
116
value
641
group Id
OG004
spread
498
value
1140
group Id
OG005
spread
1210
value
1820
group Id
OG006
spread
935
value
2510

denoms

counts
group Id
OG000
value
1
group Id
OG001
value
1
group Id
OG002
value
1
group Id
OG003
value
4
group Id
OG004
value
21
group Id
OG005
value
69
group Id
OG006
value
69
units
Participants

description

AUClast was defined as the area under the plasma or serum concentration-time curve from the time of dosing to the last measurable concentration.

dispersion Type

Standard Deviation

groups

description
Participants self-administered oral pemigatinib 1 milligram (mg) once daily (QD) on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
id
OG000
title
Part 1: Intermittent Pemigatinib 1 mg QD
description
Participants self-administered oral pemigatinib 2 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
id
OG001
title
Part 1: Intermittent Pemigatinib 2 mg QD
description
Participants self-administered oral pemigatinib 4 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
id
OG002
title
Part 1: Intermittent Pemigatinib 4 mg QD
description
Participants self-administered oral pemigatinib 6 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.
id
OG003
title
Part 1: Intermittent Pemigatinib 6 mg QD
description
Participants self-administered intermittent or continuous oral pemigatinib 9 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.
id
OG004
title
Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD
description
Participants self-administered intermittent or continuous oral pemigatinib 13.5 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.
id
OG005
title
Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD
description
Participants self-administered intermittent or continuous oral pemigatinib 20 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 20 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.
id
OG006
title
Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD

param Type

MEAN

population Description

PK/PD Population. Only participants with available data were analyzed.

reporting Status

POSTED

time Frame

Part 1: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose post-dose on Cycle 1 Day 1. Part 2: predose on Cycle 1 Day 1

title

Parts 1 and 2: AUClast After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Day 1

type

SECONDARY

unit Of Measure

hr*ng/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice